<code id='1C706A0ECE'></code><style id='1C706A0ECE'></style>
    • <acronym id='1C706A0ECE'></acronym>
      <center id='1C706A0ECE'><center id='1C706A0ECE'><tfoot id='1C706A0ECE'></tfoot></center><abbr id='1C706A0ECE'><dir id='1C706A0ECE'><tfoot id='1C706A0ECE'></tfoot><noframes id='1C706A0ECE'>

    • <optgroup id='1C706A0ECE'><strike id='1C706A0ECE'><sup id='1C706A0ECE'></sup></strike><code id='1C706A0ECE'></code></optgroup>
        1. <b id='1C706A0ECE'><label id='1C706A0ECE'><select id='1C706A0ECE'><dt id='1C706A0ECE'><span id='1C706A0ECE'></span></dt></select></label></b><u id='1C706A0ECE'></u>
          <i id='1C706A0ECE'><strike id='1C706A0ECE'><tt id='1C706A0ECE'><pre id='1C706A0ECE'></pre></tt></strike></i>

          explore

          explore

          author:entertainment    Page View:86996
          President Biden speaks on the Cancer Moonshot initiative at the John F. Kennedy Library in 2022. Evan Vucci/AP

          WASHINGTON — The next chapter of President Biden’s moonshot to end cancer has landed. While the new goals are inspiring hope among cancer researchers, not everyone is impressed.

          The president early Wednesday morning unveiled a slew of federal plans and private-sector agreements to fuel the relaunched Cancer Moonshot, a project to improve treatments and halve cancer deaths in the next 25 years. Among roughly 50 new programs and partnerships are multimillion-dollar pledges to advance testing, data pools, clinical trials and outreach efforts.

          advertisement

          It is the latest phase of a project Biden first launched as vice president in the wake of his son Beau’s death from brain cancer in 2015. But while the first moonshot funneled money almost entirely to early-stage cancer research, its sequel is broadening efforts to prevent cancer deaths — particularly through anti-smoking efforts — and introduces a new focus on research infrastructure and patient engagement that some cancer researchers have applauded.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more
          An innovative path out of biotech’s “valley of death”
          An innovative path out of biotech’s “valley of death”

          AdobeSomanypromisingmedicalinnovationsneverreachtheirfullpotentialastherapiesorcures,languishinginst

          read more
          After affirmative action ruling, medical educators look to 'holistic review'
          After affirmative action ruling, medical educators look to 'holistic review'

          AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

          read more

          Pharma budget tightening trickles down to Doximity

          AdobeYou’rereadingthewebeditionofSTATHealthTech,ourguidetohowtechistransformingthelifesciences. Sign